With 18 randomised patients, we have already reached 50% of our target in just under 6 months!
Keeping the ASCO24 slogan „Come from the science, stay for the connection, and leave with an inspiration that will drive you forward”, GBG is taking part in the following presentations this year…
Our leading experts continuously support physicians in their clinical decision-making with updated Clinical Practice Guidelines and Consensus Statements from European Society of Medical Oncology (ESMO).
The prognostic and predictive potential of CAV1/2 expression was analysed in the GeparSepto trial (GBG 069).
GBG will present several posters at the San Antonio Breast Cancer Symposium 2023
GBG Research at ESMO-Breast Cancer Conference 2023 in Berlin
